Placement Agent Agreement - CytRx Corp. and Dunwoody Brokerage Services Inc.
Placement Agent Agreement
This Placement Agent Agreement ("Agreement") dated as of September 15, 2003, is
entered into by and among CytRx Corporation ("CytRx" or the "Company"), having
its business office located at 11726 San Vincente Boulevard, Suite 650, Los
Angeles, CA 90049, and Dunwoody Brokerage Services, Inc. ("DBS"), having its
principal office located at 4243 Dunwoody Club Drive, Suite 200, Atlanta, GA
30350.
The Company has entered into an engagement letter with Cappello Capital Corp.
("Cappello") under which Cappello is to serve as the Company's exclusive
placement agent for any financing transaction, including the proposed private
placement in a "PIPE" transaction involving the sale of securities to
institutional investors (the "Offering"). Cappello has agreed to our
participation in the Offering on the terms set forth herein.
For good consideration, the receipt and sufficiency of which are acknowledged,
DBS and CytRx hereby agree as follows:
I. Scope of Services to be Provided by DBS
DBS will provide the following services during the term of this Agreement.
Capital Raising
The Company currently anticipates raising up to USD$8.5 million in the Offering.
The actual terms of the Offering will depend on market conditions, and will be
subject to negotiation among the Company, Cappello, DBS and prospective
investors; provided, however, that all terms must be acceptable to the Company
in its sole and absolute discretion.
Although we cannot guarantee CytRx that we will be able to raise new capital, we
will conduct the offering on a best efforts basis. We will offer the Company's
securities in the Offering only to those investors listed in Exhibit A hereto
and any other investors that Cappello and the Company in their sole discretion
jointly agree to in writing (collectively, the "DBS Investors"). The Company
will have no obligation to accept any subscription from any proposed investor in
the Offering or any minimum aggregate amount of subscriptions from DBS
Investors.
II. Compensation and Other Provisions Relating to Fees
A. Compensation to DBS
DBS shall be entitled to the following compensation in connection herewith:
1. Cash Fee
Upon receipt and acceptance of any funds from a DBS Investor,
CytRx agrees to pay DBS a cash fee of 3.75% of the aggregate
purchase price of the securities placed at the closing of the
Offering ("Initial Closing Date").
<PAGE>
2. Warrant
In addition, DBS shall receive a Warrant ("DBS Warrant") to
purchase a number of shares of common stock equal to 3% of the
number of shares of common stock purchased by the DBS Investor
in the Offering.
The DBS Warrant shall be delivered at the Initial Closing
Date, registered on the DBS Investor's Registration Statement,
and shall be exercisable any time until the seventh (7th)
anniversary of the Initial Closing Date hereof at one hundred
percent (100%) of the initial exercise price of the warrants
issued to the DBS Investors in the Offering, and shall provide
for cashless exercise provisions.
III. Representations and Warranties
a) The Company hereby authorizes DBS to transmit to the
prospective purchasers of the securities copies of the
Company's most recent filings with the Securities and Exchange
Commission, together with summary materials, if any, approved
in writing by the Company.
b) The Company agrees that CytRx will enter into subscription,
registration rights and other customary agreements, and that
CytRx's counsel will supply an opinion letter on the
transaction in form and substance reasonably acceptable to,
and addressed to, DBS and the investors.
c) The Company further agrees that DBS may rely upon, and are a
third party beneficiary of, the representations and
warranties, and applicable covenants, set forth in any
agreements with investors in the Offering.
d) DBS represents that the only investors to which it has offered
the Company's securities are listed in Exhibit A hereto.
IV. Status/Liability of DBS
When performing any of the services described herein, or in connection with any
special business assignment, DBS shall be deemed to be an independent
contractor. Except as expressly provided for in writing by CytRx, DBS shall have
no authority to act unilaterally on behalf of CytRx.
DBS will use its best efforts in performing its duties hereunder. DBS shall not
be liable to CytRx, for errors in judgment or for any other action undertaken or
omitted hereunder unless such error or action involves willful malfeasance,
gross negligence or fraud. Except as hereunder provided, DBS shall not be
accountable for any loss suffered by any of them.
DBS's ability to complete its assignments described herein in a satisfactory and
timely way is dependent upon the provision by CytRx of corporate or financial
records and available diligence materials, and such other information that DBS
deems material to effective completion of its work. It is further understood and
agreed that DBS and/or its designees may rely on the accuracy of such
information provided by CytRx and CytRx shall be solely responsible for the
accuracy and completeness of such records and information.
2
<PAGE>
It is also specifically understood that CytRx will employ independent legal
counsel to advise it as to contract, tax, international laws and regulations and
securities considerations in connection herewith and with all of the financing
transactions resulting here from, and that all financing documents should be
reviewed and approved by such counsel prior to the consummation of any finance
transaction.
CytRx, its corporate affiliates or its designees and successors hereby agree to
indemnify DBS and each of its officers, directors, trustees, governors,
employees, partners, shareholders, beneficiaries or agents of any of the
entities comprising DBS, against all cost and expenses, including but not
limited to, reasonable attorney's fees, for any claim by third parties made
against any of them arising out of or relating to this Agreement and all related
agreements, provided that such indemnity shall not apply if DBS shall have been
found guilty of willful malfeasance, gross negligence or fraud by a competent
court of final jurisdiction.
V. Other Activities
DBS, its affiliates, designees and assigns, now render and will continue to
render investment banking services, financial advisory, management services and
the like, to other companies which may conduct business similar to that of
CytRx. DBS shall be free to render such advice and services according to its
sole discretion and CytRx hereby consents thereto. Similarly, DBS shall not be
required to devote full time and attention to the performance of the duties
specified under this Agreement but shall only devote so much of its time and
attention as it deems reasonable and/or necessary for such purposes.
VI. Confidentiality and Non-Disclosure
DBS acknowledges that it is being provided with, and will in the future be
provided with, confidential and proprietary information concerning the business
and operations of CytRx and that such information constitutes confidential and
proprietary information owned solely by CytRx. Without the express written
consent of CytRx, DBS may not disclose to any person, legal entity or government
agency any such information except (i) to the extent that such information
otherwise is generally known to the public; (ii) pursuant to the written advice
of counsel that disclosure by DBS is required under applicable law, after
providing CytRx with reasonable advance notice of such proposed disclosure; or
(iii) pursuant to Court order. Under no circumstances may DBS use any such
information for the benefit of DBS or third parties without the express written
consent of CytRx. In cases where disclosure is made with express written consent
of CytRx, DBS may nevertheless disclose such information only upon receipt of a
confidentiality agreement from the person to whom such disclosure is to be made,
substantially in the form of this paragraph, and stated to be for the benefit of
CytRx.
3
<PAGE>
VII. Miscellaneous
A. Term
This Agreement shall continue in effect for an initial period of three (3)
months from the date of execution. If the Agreement is renewed subsequent to the
expiration of the initial period then the Agreement shall continue in effect
until terminated by either DBS or CytRx by 30 days prior written notice to the
other parties hereto. In the event that this Agreement is terminated, all earned
but unpaid fees or expense of any kind due DBS or its successors or designees
shall be paid in full prior to the effective date of the termination.
B. Non-Circumvention
Any potential DBS Investor who DBS introduces (via conference call, visit or
other means) to CytRx shall be considered for purposes of this Letter a
protected investor of DBS, whether or not such DBS Investor participates in the
offering(s) contemplated by this Letter. Note that the aforementioned protected
potential DBS Investors shall be listed on Exhibit A. In the event that CytRx
accepts an investment from a DBS Investor for a period of 24 months from the
date of introduction of said DBS Investor, CytRx agrees to pay to DBS a fee as
stated in Section II. Compensation and Other Provisions Relating to Fees at the
time of closing.
C. No Obligation
CytRx may, in their sole and absolute discretion, choose not to accept any
investment with any DBS Investor. CytRx shall have no obligation to pay DBS any
fees or issue any Stock or warrants to DBS to the extent that CytRx rejects any
proposed investor and any future investment from said DBS Investor is not
covered under Section VI. B. Non-Circumvention.
[THIS SECTION INTENTIONALLY LEFT BLANK]
4
<PAGE>
D. Venue
This Agreement shall be construed and interpreted according to the Laws of the
State of California applicable to agreements to be performed entirely within
such State.
E. Entire Agreement
This Agreement constitutes the entire Agreement between the parties and
supersedes and cancels any and all prior or contemporaneous arrangements,
understandings and agreements, written or oral, between them relating to the
subject matter hereof.
F. Effectiveness
This Agreement shall be deemed in force at the time the Agreement is executed by
both parties.
The undersigned have executed this Agreement as of this 15th day of September
2003.
DUNWOODY BROKERAGE SERVICES, INC.
By: /s/ Robert L. Hopkins
------------------------------
Robert L. Hopkins
President
Date: September 15, 2003
------------------------------
CYTRX CORPORATION
By: /s/ Steven Kreigsman
------------------------------
Steven Kriegsman
Chief Executive Officer
Date:
------------------------------
5
<PAGE>
CytRx Corporation ("CytRx")
Exhibit A
Pursuant to the executed Placement Agent Agreement ("Agreement"), CytRx hereby
confirms that DBS has permission to introduce CytRx to:
o WEC Partners, LLC
o Crescent International Ltd.
o OTATO Limited Partnership
o RAM Capital Resources, LLC
The above named investor(s) shall be covered under the terms as agreed upon in
the executed Letter. This signed Exhibit A will act as written confirmation for
DBS to make this/these introduction(s).
By: /s/ Steven Kriegsman
------------------------------
Print Name:
--------------------------
Title:
------------------------------
Date:
------------------------------
6